Roth Capital Upgrades Regeneron Pharma (REGN) to Buy

Roth Capital upgraded Regeneron Pharma (NASDAQ: REGN) from Neutral to Buy with a price target of $555.00.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $462.95 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
• Regeneron (REGN) and Mammoth Biosciences Collaborate over Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
• Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO